Martin Mihm

4.9k total citations · 1 hit paper
10 papers, 2.6k citations indexed

About

Martin Mihm is a scholar working on Oncology, Molecular Biology and Dermatology. According to data from OpenAlex, Martin Mihm has authored 10 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Molecular Biology and 2 papers in Dermatology. Recurrent topics in Martin Mihm's work include Cutaneous Melanoma Detection and Management (7 papers), Melanoma and MAPK Pathways (4 papers) and melanin and skin pigmentation (2 papers). Martin Mihm is often cited by papers focused on Cutaneous Melanoma Detection and Management (7 papers), Melanoma and MAPK Pathways (4 papers) and melanin and skin pigmentation (2 papers). Martin Mihm collaborates with scholars based in United States, Australia and France. Martin Mihm's co-authors include Michael B. Atkins, Merrick I. Ross, Douglas S. Reintgen, Antônio C. Buzaid, John A. Thompson, Donald L. Morton, Jeffrey E. Gershenwald, Natale Cascinelli, Kelly M. McMasters and Alan N. Houghton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Martin Mihm

9 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma

2001 2.0k citations Charles M. Balch, Antônio C. Buzaid et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Martin Mihm

Since Specialization

Citations

This map shows the geographic impact of Martin Mihm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Mihm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Mihm more than expected).

Fields of papers citing papers by Martin Mihm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Mihm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Mihm. The network helps show where Martin Mihm may publish in the future.

Co-authorship network of co-authors of Martin Mihm

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Mihm. A scholar is included among the top collaborators of Martin Mihm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Mihm. Martin Mihm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study 2025 ·Annals of Oncology ·Christof Vulsteke, (unknown), Pongwut Danchaivijitr, (unknown), Alejo Rodríguez‐Vida, Zuo‐Feng Zhang, (unknown), (unknown), Steffen Rausch, (unknown), (unknown), (unknown), (unknown), Peter H. O’Donnell, Martin Mihm, Changting Meng, (unknown), (unknown), Blanca Homet Moreno, (unknown)	1
2	A NEW MATHEMATICS, AND NEW COMPARATIVE EFFECTIVENESS CALCULATORS (CancerMath.net), FOR PREDICTING MELANOMA DEATH 2009 ·(unknown), (unknown), Sebastian M. Jara, (unknown), Kenneth K. Tanabe, Arthur J. Sober, Martin Mihm, Jerry Younger, Kevin S. Emerick, James Michaelson, (unknown)	1
3	Current concepts of metastasis in melanoma 2008 ·Expert Review of Dermatology ·Blazej Zbytek, J. Andrew Carlson, Jacqueline Granese, Jeffrey S. Ross, Martin Mihm, Andrzej Słomiński	182
4	What is new in melanoma research: genetics and epidemiology of melanoma in 2003? Review of a workshop held in Milan in May 2003 2004 ·Melanoma Research ·Giovanna Bianchi‐Scarrà, Alessandro Testori, Martin Mihm	3
5	Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF) 2004 ·Journal of Clinical Oncology ·(unknown), Michael V. Seiden, Marcus O. Butler, Frank G. Haluska, Israel Lowy, (unknown), David B. Lautz, Martin Mihm, Glen Dranoff	0
6	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response. 2004 ·Blood ·Stefano Monti, Kerry J. Savage, Jeffery L. Kutok, Friedrich Feuerhake, Paul J. Kurtin, Martin Mihm, Bingyan Wu, (unknown), Donna Neuberg, Ricardo C.T. Aguiar, Paola Dal Cin, Christine Ladd, Geraldine S. Pinkus, Gilles Salles, Nancy L. Harris, Riccardo Dalla‐Favera, Thomas M. Habermann, Jon C. Aster, Todd R. Golub, Margaret A. Shipp	18
7	New TNM melanoma staging system: Linking biology and natural history to clinical outcomes 2003 ·Seminars in Surgical Oncology ·Charles M. Balch, Antônio C. Buzaid, Seng‐Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan N. Houghton, John M. Kirkwood, Kelly M. McMasters, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, John A. Thompson, John F. Thompson	93
8	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma breakdown → 2001 ·Journal of Clinical Oncology ·Charles M. Balch, Antônio C. Buzaid, Seng‐Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan N. Houghton, John M. Kirkwood, Kelly M. McMasters, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, John A. Thompson, John F. Thompson	1995
9	A new American Joint Committee on Cancer staging system for cutaneous melanoma 2000 ·Cancer ·Charles M. Balch, Antônio C. Buzaid, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Alan N. Houghton, John M. Kirkwood, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, Seng-Jaw Soong, John A. Thompson, John F. Thompson, Jeffrey E. Gershenwald, Kelly M. McMasters	325
10	Recommendations for the Reporting of Tissues Removed as Part of the Surgical Treatment of Cutaneous Melanoma 1998 ·American Journal of Clinical Pathology ·Alistair J. Cochran, Christiane Bailly, Martin Cook, Kerry A. Crotty, S. McCarthy, Martin Mihm, (unknown), Richard W. Sagebiel	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact